GeneDx Holdings Corp. has announced new data and presentations related to genomic newborn screening (gNBS) at the upcoming International Consortium on Newborn Sequencing (ICoNS) 2025. The company will present findings from studies involving over 22,000 newborns, including operational and technical insights from the GUARDIAN study, which implemented scalable and equitable gNBS in more than 17,000 newborns. These results will be presented at ICoNS, with sessions covering real-world learnings, follow-up data from the first 15,000 participants, and key lessons learned since the launch of the GUARDIAN expanded newborn screening study.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251022665772) on October 22, 2025, and is solely responsible for the information contained therein.